Effectiveness of Naproxen for the Prevention of Heterotopic Ossification After Complex Elbow Trauma: a Prospective Randomized Trial
Overview
- Phase
- Phase 4
- Status
- Withdrawn
- Locations
- 1
- Primary Endpoint
- There is no difference in ulnohumeral flexion
Overview
Brief Summary
Complex elbow fractures can lead to formation of new bone (called Heterotopic ossification). This new bone is unwanted and it can restrict motion. This research study is being done to learn more about the effect of the drug naproxen, on unwanted formation of new bone around the elbow as it heals after a fracture. Naproxen belongs to a class of drugs called NSAIDs which stands for non-steroidal anti-inflammatory drugs.
Several research studies suggest that NSAIDs such as Naproxen can prevent the unwanted formation of new bone around the hip. The effect of NSAIDS on the formation of bone around the elbow has not been studied as well as it has been studied for their effect on the hip.
The drug, Naproxen is approved by the US food and drug administration (FDA) for sale but ot specifically for the treatment of heterotopic ossification.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects aged 18 years or greater
- •Operative treatment of one of the following injuries
- •An elbow dislocation with or without associated fractures
- •An olecranon fracture-dislocation, but not simple olecranon fractures
- •A distal humerus fracture
Exclusion Criteria
- •An existing diagnosis of one of the following conditions
- •Injury to the central nervous system, thorax, or abdomen precluding the immediate use of non-steroidal anti-inflammatory medications
- •Fracture of any long bone since non-steroidal anti-inflammatory medications may increase the risk of nonunion
- •History of gastritis, peptic ulcer disease, or upper gastrointestinal bleeding
- •Impaired renal function (creatinine \> 2.0), hypovolemia, heart failure, high blood pressure ( \> 160/90), fluid retention, asthma, liver dysfunction (bilirubin \> 2.0), or a coagulation disorder
- •Allergy to non-steroidal anti-inflammatory medications
- •Asthma, nasal polyps, urticaria, and hypotension associated with the use of NSAIDs
- •Considerable dehydration
- •Pregnant or breast-feeding women
- •Concomitant use of one of the following drugs:
Arms & Interventions
1
Will receive 500 mg Naproxen twice a day for two weeks
Intervention: Naproxen (Drug)
Outcomes
Primary Outcomes
There is no difference in ulnohumeral flexion
Time Frame: 2 weeks
Secondary Outcomes
No secondary outcomes reported
Investigators
David C. Ring, MD
Director of Research, Hand Service
Massachusetts General Hospital